Reset filter
Trefwoorden
Concomitant Medication ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

467 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Concomitant Medication Multiple Sclerosis ALAIN01 NCT02419378

- 28/05/2016 - 1 Formulier, 2 Itemgroepen, 14 Data-elementen, 1 Taal
Itemgroepen: Concomitant Medication, Concomitant Medication
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany

NINDS CDE Drugs Epilepsy - Drugs

- 25/04/2016 - 1 Formulier, 4 Itemgroepen, 58 Data-elementen, 1 Taal
Itemgroepen: Anti Epileptic Drug (AED) Plasma Concentration Log, Anti Epileptic Drug (AED) Resistance Log, Anti Epileptic Drug (AED) Log, Non Anti Epileptic Medication Log
NINDS Common Data Elements Used from the National Institute of Neurological Disorders and Stroke Common Data Elements (https://www.commondataelements.ninds.nih.gov/) References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials. 2012;9(3):322-9.

NINDS CDE Prior and Concomitant Medications Amyotrophic Lateral Sclerosis - Prior and Concomitant Medications

- 15/04/2016 - 1 Formulier, 1 Itemgroep, 14 Data-elementen, 1 Taal
Itemgroep: Prior and Concomitant Medications
NINDS Common Data Elements [Magnetic Resonance Imaging][Amyotrophic Lateral Sclerosis] Used from the National Institute of Neurological Disorders and Stroke Common Data Elements (https://www.commondataelements.ninds.nih.gov/) References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials. 2012;9(3):322-9.

Concomitant medication Ponderosa CML ZKSJ0083 - Concomitant medication

- 20/03/2016 - 1 Formulier, 1 Itemgroep, 8 Data-elementen, 1 Taal
Itemgroep: Concomitant medication
Study part: Concomitant medication.Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Concomitant medication LenaMain-Study - Concomitant Medication

- 17/03/2016 - 1 Formulier, 1 Itemgroep, 11 Data-elementen, 1 Taal
Itemgroep: Concomitant medication
A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Protocol-Code: RV-MM-PI-280 EudraCT-Number: 2007-003945-33 Author: Claus Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr. med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann, Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-Studie: Prof. Roland Fenk, Düsseldorf Coordinating center for clinical trial Medical faculty of University Hospital Heinrich-Heine-University Scientific Director: Herr Dr. J. Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0) 211-81-19701 Fax: +49 (0) 211-81-19702

Concomitant medication Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv - Case Report Form (HIPEC) Concomitant medication

- 17/02/2016 - 1 Formulier, 1 Itemgroep, 11 Data-elementen, 1 Taal
Itemgroep: Concomitant Medication Form
Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv EudraCT Nr.: 2010-024352-28 Principal investigator und authorized representative of Sponsor: PD Dr. med. Oliver Zivanovic Center for Obstetrics and Gynaecology University Hospital Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor: Rheinische Friedrich-Wilhelms-Universität Bonn represented by the Dean of Medical Faculty

Concomitant Medication AML Pazopanib NCT01361334

- 11/02/2016 - 1 Formulier, 1 Itemgroep, 50 Data-elementen, 2 Talen
Itemgroep: Concomitant Medication
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Concomitant Medication AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Concomitant Medication AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 11/02/2016 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Concomitant Medication, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Medication SIMPLIFy TAVI Transcatheter Aortic Valve Implantation Without Predilation NCT01539746 - Medication NCT01539746

- 04/02/2016 - 1 Formulier, 1 Itemgroep, 10 Data-elementen, 1 Taal
Itemgroep: Medication
Use of the Self-Expanding CoreValve Prosthesis without Predilation in Patients with Significantly IMPaired Left-VentrIcular Ejection Fraction for Transcatheter Aortic Valve Implantation Study. Form is used in following visits: - Visit 4 (7 days +1d) - Visit 5 (30 days +15d) - Visit 6 (180 day +-30d) - Visit 7 (1 year +1m) Projektleiter (LKP): Prof. Dr. med. Georg Nickenig Medizinische Klinik und Poliklinik II Sigmund-Freud-Str. 25, 53125 Bonn Tel. 0228-287-15217, Fax 0228-287-16423 Email: georg.nickenig@ukb.uni-bonn.de

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487- End of Treatment - Supplemental page

- 06/08/2015 - 5 Formulieren, 22 Itemgroepen, 81 Data-elementen, 1 Taal
Itemgroepen: EXCEPTION, PREVIOUS AND CURRENT MEDICATIONS, PRE-TREATMENT EVENTS, BONE MARROW BIOPSY/ ASPIRATE, ELECTROCARDIOGRAM, CHEST X-RAY, TRANSFUSIONS, FLUORESCENT IN SITU HYBRIDIZATION, EXTERNAL DATA TRACKING, LABORATORY TEST RESULTS, DRUG DISPENSATION, BMS-354825 DOSING, CONCOMITANT MEDICATIONS, NON-SERIOUS ADVERSE EVENTS, DEATH DATA, ENROLLMENT IN PREVIOUS BMS CA180 PROTOCOL, DOSE ADMINISTRATION FOR UNSCHEDULED CSF, CSF PHARMACOKINETICS, BLOOD PHARMACOKINETICS, DOSE ADMINISTRATION, PLEURAL OR OTHER BODY FLUID PHARMACOKINETICS, DIAGNOSTIC PROCEDURES
Study documentation part: End of treatment. This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487- End of Treatment

10 Itemgroepen 46 Data-elementen

Serious Adverse Event (SAE)- Form

3 Itemgroepen 36 Data-elementen

Pharmacokinetics

4 Itemgroepen 22 Data-elementen

Follow- Up

3 Itemgroepen 11 Data-elementen

Melanoma Concomitant Medication NCT00110019 - Concomitant Medication Melanoma NCT00110019 E2603 No. 2169

- 26/03/2015 - 1 Formulier, 2 Itemgroepen, 29 Data-elementen, 2 Talen
Itemgroepen: Header, Concomitant Medication
E2603 Concomitant Medication Form Form No. 2169 Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma NCT00110019 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E7D649ED-D8C9-54BD-E034-0003BA3F9857

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial